Skip to main content


Details of the Drug
Generic Name:
Drug Type:
BTK inhibitor
How the Drug is Given:

By mouth


Indications and Usage

Ibrutinib has been FDA-approved to treat:

  • Patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
  • Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (SLL) with 17p deletion.
  • Patients with Waldenström macroglobulinemia (WM).
  • Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.

Side effects needing medical attention

Low blood platelet count; diarrhea; low white blood cell count; low red blood cell count; fatigue; muscle and bone pain; swelling of legs and feet; upper respiratory tract infection; nausea; bruising; shortness of breath; constipation; rash; stomach (abdomen) pain; vomiting; decreased appetite; fever; joint pain; mouth sores; sinus infection; and dizziness.

Serious side effects

Bleeding problems; infections; decrease in blood cell counts; kidney problems; second primary cancers. 

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.